Business Context and Reporting Period
This Form 8-K was filed by ReWalk Robotics Ltd. (trading symbol: RWLK) on May 11, 2020. The filing addresses two primary events: the resolution of a Nasdaq listing compliance issue regarding minimum bid price and a delay in the filing of the Company's quarterly report for the period ended March 31, 2020, due to the COVID-19 pandemic.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that the Company is unable to file its Q1 2020 Form 10-Q by the original deadline due to operational disruptions caused by the pandemic.
Material Changes and Events
- Nasdaq Compliance: The Company previously received notice on March 24, 2020, of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a minimum bid price below $1.00. On May 11, 2020, the Company received notice that it has regained compliance and the matter is closed.
- Reporting Delay: The Company is utilizing SEC relief to extend the filing deadline for its Q1 2020 Form 10-Q by up to 45 days. The report is expected to be filed by June 3, 2020, and no later than June 29, 2020.
- Operational Disruption: The Company temporarily closed its corporate headquarters and shifted to remote work, hindering the preparation of financial statements.
Guidance, Outlook, and Risks
Management has supplemented its risk factors to highlight the material adverse impact of the COVID-19 pandemic on its business operations and financial results. Specific risks and outlook items include:
- Sales Impact: Direct sales activities and patient training have been curtailed, adversely impacting Q1 2020 revenues. The Company notes difficulty in forecasting future requirements and engaging new clients.
- Repairs and Logistics: Inability to repair existing systems has necessitated shipping temporary replacements. Uncertainty remains regarding when restrictions will lift and if future sales will offset forgone revenue.
- Production and Supply Chain: Manufacturing faces potential delays due to supply chain disruptions and government directives. There is an increased risk of overproduction or underproduction relative to sales.
- Regulatory and Clinical Trials: Travel limitations and business closures may delay patient enrollment, investigator recruitment, and regulatory approvals in the U.S. and Europe.
- Liquidity and Receivables: Future liquidity could be adversely impacted by delays in customer payments and potential economic downturns affecting capital access.
Investor Verification Checklist
- Verify the actual filing date of the Q1 2020 Form 10-Q to confirm if it was submitted by the extended deadline of June 29, 2020.
- Review the Q1 2020 Form 10-Q once filed to quantify the specific revenue decline and cash burn rate attributed to the pandemic.
- Monitor the Company's cash position and liquidity runway given the stated risks of delayed receivables and potential capital access restrictions.
- Track the status of clinical trials and regulatory approvals to assess potential delays in product development timelines.
- Confirm the current status of the Nasdaq listing to ensure continued compliance with Rule 5550(a)(2).